INSIGHTS ON DRUG DEVELOPMENT

• Simplify Process Scale-Up With An Innovative Single-Use Bioreactor

  Consistent cell growth and protein yields from 5 L to 5,000 L show how a unified bioreactor design can simplify scale-up, reduce risk, and accelerate upstream process development in bioproduction.

• Softgel Formulation Strategies For Challenging Oral Compounds

  Explore strategies to solve solubility and permeability challenges, boost oral bioavailability, and ensure consistent absorption — reducing risk and unlocking complex molecules.

• Navigating Emerging Therapeutics: Cannabinoid And Psilocybin Drug Development

  Cannabinoid and psilocybin therapies are advancing rapidly, and Mikart supports innovators with DEA-licensed facilities, formulation expertise, regulatory guidance, and manufacturing capabilities from clinical development to commercialization.

• Ask Us Anything: Miles Blackburn On Advances In Flow And Radical Chemistry

  Miles Blackburn, Associate Director of Chemistry at Snapdragon Chemistry, on why the biggest payoff of flow and radical chemistry is speed — processes that scale fast enough to get intermediates and APIs delivered on a clinical timeline.

• Complementary Methodologies For Analysis Of NISTmAb Impurities

  2/27/2026

  Gain insight into how SEC and CE‑SDS complement each other to assess monoclonal antibody size variants, offering stronger insight into aggregates, fragments, and overall purity.

• Navigating The Regulatory Space To Biosimilar Approval

  9/1/2025

  The biosimilar patent cliff is reshaping pharma, creating unprecedented opportunities for biotech and CDMOs. Explore expert regulatory support that can help you navigate this shift with confidence.

• Detect Low-Abundance GLP-1 Impurities With Greater Sensitivity

  8/24/2026

  Low-level impurities can be difficult to resolve using conventional approaches. Discover how a Charged Surface 2.3 µm superficially porous Phenyl-Hexyl column enhances reversed-phase LC-MS analysis.

• mRNA LNPs Drive Safe, Effective Repeat Dosing In Disease Models

  6/19/2026

  Repeat dosing may be essential for long-term mRNA applications. Explore safety, immune-response, and efficacy findings from multiple LNP administrations, including a nine-dose evaluation over six months.

• Overcoming API Constraints And Tight Timelines With On-Demand Manufacturing

  3/20/2026

  Use innovative lipid-based formulations and on-demand manufacturing to accelerate Phase 1 trials, enable flexible dose escalation, and maximize limited API for poorly soluble compounds.